Effectiveness of methyl-GAG (NSC-32946) administered intramuscularly.
D000447:Aldehydes / Q000627:therapeutic use*; D000578:Amidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006037:Glyoxal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D012877:Skin Manifestations
D000447:Aldehydes; D000578:Amidines; D000970:Antineoplastic Agents; D006835:Hydrazones; D006037:Glyoxal